RA Capital, a 10% Owner and Director, Makes Substantial $172M Post-IPO Investment in Hemab Therapeutics

summarizeSummary

RA Capital Healthcare Fund LP, a 10% owner and director, significantly increased its stake in Hemab Therapeutics Holdings, Inc. with over $172 million in combined open market purchases and preferred stock conversions following the company's recent IPO.

check_boxKey Events

• Significant Insider Investment

  RA Capital Healthcare Fund LP, a 10% owner and director, acquired shares totaling over $172 million through a combination of open market purchases and preferred stock conversions.

• Post-IPO Confidence

  The transactions include open market purchases of common stock valued at over $52 million, with prices ranging from the IPO price of $18.00 up to $25.00 per share, demonstrating conviction above the initial offering price.

• Timing After Upsized IPO

  These transactions occurred between May 4-6, 2026, immediately following Hemab Therapeutics' recently completed upsized initial public offering, which was priced at $18.00 per share.

auto_awesomeAnalysis

This Form 4 filing indicates a strong vote of confidence from RA Capital Healthcare Fund LP, a major institutional investor with board representation, in Hemab Therapeutics Holdings, Inc. The combined open market purchases and preferred stock conversions, totaling over $172 million, represent a substantial investment following the company's recent upsized IPO. The open market purchases, some made above the IPO price, suggest that RA Capital sees significant value in the company post-listing. This large insider buying activity from a key investor and director group could be interpreted positively by the market, signaling strong conviction in Hemab's future prospects.